Hotstocked Newsletters

Promoted Companies

PROMOTION HISTORY
SORT BY:

ONCOSEC MEDICAL (ONCS)

Total paid for Promotions this month: $5,000
E-mails this Month: 2
Estimated Volume Generated: $0
Research Report on ONCS: Click to see
* The information presented is based on information for Sep , 2015
  //         ​   ​   OncoSec Medical (NASDAQ:ONCS) receives upgrade from Zacks           ​   ​ ​ ​   ​   OncoSec Medical Inc  For over four years, OncoSec (ONCS) has been a somewhat ignored and under-appreciated ...read more
Promoter: InsideWallStreetReport.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCS $5,000 UNKNOWN
Max Profit: 0.16 % Gain at close: Pending
  //         ​   ​   OncoSec Medical (NASDAQ:ONCS) receives upgrade from Zacks           ​   ​ ​ ​   ​   OncoSec Medical Inc  For over four years, OncoSec (ONCS) has been a somewhat ignored and under-appreciated ...read more
Promoter: InsideWallStreetReport.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCS $5,000 UNKNOWN
Max Profit: 0.16 % Gain at close: Pending
  //         ​   ​   OncoSec Medical (NASDAQ:ONCS) receives upgrade from Zacks           ​   ​ ​ ​   ​   OncoSec Medical Inc  For over four years, OncoSec (ONCS) has been a somewhat ignored and under-appreciated ...read more
Promoter: InsideWallStreetReport.com Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
ONCS $5,000 UNKNOWN
Max Profit: 2.17 % Gain at close: Pending
      OncoSec Medical (NASDAQ:ONCS) receives $25 price target and Buy rating from leading analyst Expert analysts at HC Wainright has Buy rating on OncoSec Medical Inc (OTC:ONCS). The firm has started coverage in an analyst report made public on Tuesday morning. HC Wainright's target would suggest upside of 246.74% from the company's last stock close. The new coverage is welcomed by equity ...read more
Promoter: InsideWallStreetReport.com Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
ONCS $5,000 UNKNOWN
Max Profit: 2.17 % Gain at close: Pending
      OncoSec Medical (NASDAQ:ONCS) receives $25 price target and Buy rating from leading analyst Expert analysts at HC Wainright has Buy rating on OncoSec Medical Inc (OTC:ONCS). The firm has started coverage in an analyst report made public on Tuesday morning. HC Wainright's target would suggest upside of 246.74% from the company's last stock close. The new coverage is welcomed by equity ...read more
Promoter: InsideWallStreetReport.com Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
ONCS $5,000 UNKNOWN
Max Profit: 2.17 % Gain at close: Pending
      OncoSec Medical (NASDAQ:ONCS) receives $25 price target and Buy rating from leading analyst Expert analysts at HC Wainright has Buy rating on OncoSec Medical Inc (OTC:ONCS). The firm has started coverage in an analyst report made public on Tuesday morning. HC Wainright's target would suggest upside of 246.74% from the company's last stock close. The new coverage is welcomed by equity ...read more
Promoter: InsideWallStreetReport.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCS Unknown compensation UNKNOWN
Max Profit: 4.10 % Gain at close: Pending
Tonny     Time for the ONCS squeeze soon!    OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse    http://finance.yahoo.com/news/oncosec-medical-announces-phase-ii-110200554.html OncoSec Announces Promising Phase 2 Result For Cancer Immunotherapy OncoSec reported positive Phase 2 trial results for its cancer immunotherapy, ImmunoPulse IL-12, in treating ...read more
Promoter: Stockpalooza.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCS $10,000 UNKNOWN
Max Profit: 0.41 % Gain at close: Pending
ONCS: Results from Newly Initiated Phase II Combination Trial Could Lead to a Big License Deal Earlier today, OncoSec Medical (ONCS) announced the initiation of a landmark Phase IIcombination trial in collaboration with the UCSF and Merck to evaluate the safety, tolerability and efficacy of Merck’s anti-PD-1 drug, KEYTRUDA® (pembrolizumab) in combination with OncoSec’s ImmunoPulse therapy ...read more
Promoter: Stockpalooza.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCS $10,000 2,540,696
Max Profit: 19.09 % Gain at close: 14.33 %
Hi Tonny    Here is something special for you.   News out on ONCS http://finance.yahoo.com/news/uc-san-francisco-oncosec-medical-080100294.html Ticker: ONCS November 25, 2014 OncoSec Medical, Merck, and UC San Francisco Collaborate on Landmark Immunotherapy Trial OncoSec Medical Inc. (ONCS) is changing ...read more
Promoter: Stockpalooza.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCS $10,000 2,540,696
Max Profit: 19.09 % Gain at close: 14.33 %
  Morning Members, yesterday I racked up more than $1,000 in profits and my SuperNova Elite newsletter cashed in on several trades. Today I will share with YOU a few stocks WE are potentially playing... A few stocks I would watch today are:   MULI - here is a big risk promo play but the bounces have been nice. If they do what they say they are going to do, we could see MULI test $.70 today for a scalp for 10%. Yesterdays support ...read more
Promoter: Stock Analyzer Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCS Unknown compensation UNKNOWN
Max Profit: 8.98 % Gain at close: Pending
First  >> Last
Video not found or You must install the Flash Plugin for your Browser in order to view this movie